← Back to scoreboard
HealthcareABBV
AbbVie
AI story is primarily pipeline survival, not frontier AI play. Humira collapse driving transition to Skyrizi/Rinvoq ($31B+ projected by 2027). ARCH platform connects 200+ data sources but mid-tier adopter.
AI Impact Score
6.3/10
↑ Positive
Scoring Breakdown
Sector Base
7
AI Revenue Exposure
6
Moat Durability
7
Disruption Risk (lower=better)
5
AI Adoption Maturity
7
Scenarios
Bull Case
Skyrizi/Rinvoq already executing Humira replacement. ARCH's 200+ source data platform gives long-term advantage in immunology target identification.
Bear Case
AI adoption concentrated in internal tooling with no high-profile external collaborations. Less urgency to accelerate AI while executing commercial transition.
Key Factors to Watch
- ●ARCH platform connects 200+ internal/external data sources
- ●BigHat Biosciences partnership for ML antibody discovery — pre-clinical, mid-tier scale
- ●Humira cliff largely navigated, reducing AI urgency vs. competitors building moats now
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-04-10 | 6.3 | Positive | Score 6.2→6.3 (rounding drift correction — dimensions unchanged, formula recomputed to match stored value) |
| 2026-03-08 | 6.2 | Positive | Score 6.4→6.2 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 6.4 | Positive | Score 6.2->6.4 (aam 6->7). External research cross-ref: ARCH platform with 2B+ data points across 200 sources, Gaia tool 40-60% time savings, BigHat + Anima partnerships |
| 2026-03-08 | 6.2 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-04-25
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.